Benzinga··Vandana SinghRegeneron Stock Tumbles 10% After Melanoma Trial Fails Statistical Hurdle
Regeneron stock drops 10% after fianlimab melanoma trial misses statistical significance despite numerical benefit. Company announces Telix partnership for radiopharmaceutical therapies.
MRKTLXREGNprogression-free survivalmelanoma